Compounding is still permitted case by case for an individual patient when a provider documents a specific clinical need, so availability is now a medical decision rather than an open program
et par voie P.O., dans les conditions des essais, tait de 77,5 M/kg
It is a synthetic version of the naturally-occurring growth hormone-releasing hormone, and has been found to be safe and effective in clinical trials
To explore how our personalized, medically supervised programs can support your unique health goals, we invite you to take our free assessment quiz today
The company stated that no generic versions of semaglutide are currently available and described compounded alternatives as "unapproved fake or illegitimate knockoffs" that could "expose patients to serious safety and efficacy risks." As part of their effort to address this issue, Novo Nordisk has advocated for semaglutide to be added to the FDAs list of drugs that present "demonstrable difficulties for compounding." FDAs Decision and Timelines In February, the FDA declared that the semaglutide shortage was officially over
Villareal DT, Aguirre L, Gurney AB, et al
